Becton Dickinson (NYSE:BDX) said today it closed a $460.7 million offer to repurchase outstanding 3% notes due 2026.
The Franklin Lakes, N.J.-based company said that the amount it repurchased represents approximately 98% of the total outstanding aggregate principal amount of notes.
Individuals who still hold the notes are entitled to receive cash equal to 101% of the principal amount of the notes, equivalent to $1,015.58 per $1,000 in principal amount of notes tendered with an expected settlement date of March 6, according to an SEC filing.
Last month, Becton Dickinson said it closed the divestiture of its soft tissue core needle biopsy line and Aspira product line to Merit Medical (NSDQ:MMSI) for $100 million.
